Animal models of regenerative medicine

J. Koudy Williams, James Yoo, Anthony Atala

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In the process of scientific discovery and eventual translation of this information to the clinic, a fundamental step is exploration of the safety and efficacy of these discoveries in preclinical studies. These questions are addressed in animal models that provide a sufficient level of reproducibility. Fundamental discovery also demands animal systems in which reagents (e.g., antibodies and probes) are readily available and turnover of individuals and the occurrence of biologic events are rapid. Therefore, the study of animals with short development and life cycles (days to months) provides the best opportunities for initial detection and observation of the process under study. Common choices for initial feasibility research include Drosophila melanogaster (fruit fly), Caenorhabditis elegans (nematode worm), Danio rerio (zebra fish), and many varieties of Mus musculus (mouse) and Rattus norvegicus (rat). Development of knockout and transgenic animals has greatly increased the rate of fundamental biologic discovery in the past decade. Feasibility testing is almost always performed in small mammals, specifically mice and rats, in which outcomes can be determined after relatively short periods of observation; reagents are readily available; and the variations in radiographic, imaging, histologic, or biochemical outcomes among individuals are small. Many standard models for the assessment of implant materials in small mammals have been described in standard protocol documents published by major standards and regulatory organizations, including the American Society for Testing and Materials (ASTM), International Standards Organization (ISO), U.S. Food and Drug Administration (FDA), and European Commission.

Original languageEnglish (US)
Title of host publicationRegenerative Pharmacology
PublisherCambridge University Press
Pages219-234
Number of pages16
ISBN (Print)9781139047357, 9780521899499
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Regenerative Medicine
Animal Models
Zebrafish
Mammals
Observation
Organizations
Materials Testing
Genetically Modified Animals
Caenorhabditis elegans
United States Food and Drug Administration
Life Cycle Stages
Drosophila melanogaster
Drosophila
Safety
Antibodies
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Koudy Williams, J., Yoo, J., & Atala, A. (2011). Animal models of regenerative medicine. In Regenerative Pharmacology (pp. 219-234). Cambridge University Press. https://doi.org/10.1017/CBO9781139047357.013

Animal models of regenerative medicine. / Koudy Williams, J.; Yoo, James; Atala, Anthony.

Regenerative Pharmacology. Cambridge University Press, 2011. p. 219-234.

Research output: Chapter in Book/Report/Conference proceedingChapter

Koudy Williams, J, Yoo, J & Atala, A 2011, Animal models of regenerative medicine. in Regenerative Pharmacology. Cambridge University Press, pp. 219-234. https://doi.org/10.1017/CBO9781139047357.013
Koudy Williams J, Yoo J, Atala A. Animal models of regenerative medicine. In Regenerative Pharmacology. Cambridge University Press. 2011. p. 219-234 https://doi.org/10.1017/CBO9781139047357.013
Koudy Williams, J. ; Yoo, James ; Atala, Anthony. / Animal models of regenerative medicine. Regenerative Pharmacology. Cambridge University Press, 2011. pp. 219-234
@inbook{0628336f11c444babdbbd3e0618bbc50,
title = "Animal models of regenerative medicine",
abstract = "In the process of scientific discovery and eventual translation of this information to the clinic, a fundamental step is exploration of the safety and efficacy of these discoveries in preclinical studies. These questions are addressed in animal models that provide a sufficient level of reproducibility. Fundamental discovery also demands animal systems in which reagents (e.g., antibodies and probes) are readily available and turnover of individuals and the occurrence of biologic events are rapid. Therefore, the study of animals with short development and life cycles (days to months) provides the best opportunities for initial detection and observation of the process under study. Common choices for initial feasibility research include Drosophila melanogaster (fruit fly), Caenorhabditis elegans (nematode worm), Danio rerio (zebra fish), and many varieties of Mus musculus (mouse) and Rattus norvegicus (rat). Development of knockout and transgenic animals has greatly increased the rate of fundamental biologic discovery in the past decade. Feasibility testing is almost always performed in small mammals, specifically mice and rats, in which outcomes can be determined after relatively short periods of observation; reagents are readily available; and the variations in radiographic, imaging, histologic, or biochemical outcomes among individuals are small. Many standard models for the assessment of implant materials in small mammals have been described in standard protocol documents published by major standards and regulatory organizations, including the American Society for Testing and Materials (ASTM), International Standards Organization (ISO), U.S. Food and Drug Administration (FDA), and European Commission.",
author = "{Koudy Williams}, J. and James Yoo and Anthony Atala",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9781139047357.013",
language = "English (US)",
isbn = "9781139047357",
pages = "219--234",
booktitle = "Regenerative Pharmacology",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Animal models of regenerative medicine

AU - Koudy Williams, J.

AU - Yoo, James

AU - Atala, Anthony

PY - 2011/1/1

Y1 - 2011/1/1

N2 - In the process of scientific discovery and eventual translation of this information to the clinic, a fundamental step is exploration of the safety and efficacy of these discoveries in preclinical studies. These questions are addressed in animal models that provide a sufficient level of reproducibility. Fundamental discovery also demands animal systems in which reagents (e.g., antibodies and probes) are readily available and turnover of individuals and the occurrence of biologic events are rapid. Therefore, the study of animals with short development and life cycles (days to months) provides the best opportunities for initial detection and observation of the process under study. Common choices for initial feasibility research include Drosophila melanogaster (fruit fly), Caenorhabditis elegans (nematode worm), Danio rerio (zebra fish), and many varieties of Mus musculus (mouse) and Rattus norvegicus (rat). Development of knockout and transgenic animals has greatly increased the rate of fundamental biologic discovery in the past decade. Feasibility testing is almost always performed in small mammals, specifically mice and rats, in which outcomes can be determined after relatively short periods of observation; reagents are readily available; and the variations in radiographic, imaging, histologic, or biochemical outcomes among individuals are small. Many standard models for the assessment of implant materials in small mammals have been described in standard protocol documents published by major standards and regulatory organizations, including the American Society for Testing and Materials (ASTM), International Standards Organization (ISO), U.S. Food and Drug Administration (FDA), and European Commission.

AB - In the process of scientific discovery and eventual translation of this information to the clinic, a fundamental step is exploration of the safety and efficacy of these discoveries in preclinical studies. These questions are addressed in animal models that provide a sufficient level of reproducibility. Fundamental discovery also demands animal systems in which reagents (e.g., antibodies and probes) are readily available and turnover of individuals and the occurrence of biologic events are rapid. Therefore, the study of animals with short development and life cycles (days to months) provides the best opportunities for initial detection and observation of the process under study. Common choices for initial feasibility research include Drosophila melanogaster (fruit fly), Caenorhabditis elegans (nematode worm), Danio rerio (zebra fish), and many varieties of Mus musculus (mouse) and Rattus norvegicus (rat). Development of knockout and transgenic animals has greatly increased the rate of fundamental biologic discovery in the past decade. Feasibility testing is almost always performed in small mammals, specifically mice and rats, in which outcomes can be determined after relatively short periods of observation; reagents are readily available; and the variations in radiographic, imaging, histologic, or biochemical outcomes among individuals are small. Many standard models for the assessment of implant materials in small mammals have been described in standard protocol documents published by major standards and regulatory organizations, including the American Society for Testing and Materials (ASTM), International Standards Organization (ISO), U.S. Food and Drug Administration (FDA), and European Commission.

UR - http://www.scopus.com/inward/record.url?scp=84928060390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928060390&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139047357.013

DO - 10.1017/CBO9781139047357.013

M3 - Chapter

SN - 9781139047357

SN - 9780521899499

SP - 219

EP - 234

BT - Regenerative Pharmacology

PB - Cambridge University Press

ER -